Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58%

None

Scienture Holdings (SCNX) reported second-quarter 2026 revenue of $343,639, up approximately 510% sequentially from $56,325 in the first quarter. Net loss was $2.8 million, compared with a $6.7 million loss a year earlier, while basic and diluted net loss per share was $0.07.

The company reported a 97.7% gross margin for the quarter and said it commenced the commercial launch of REZENOPY, its second commercial product.

  • Q2 revenue was $343,639; first-half revenue totaled $399,964.
  • Q2 gross profit was $335,779, compared with zero in the prior-year quarter.
  • Operating expenses declined approximately 41% year over year to $3.0 million.
  • Operating loss was $2.7 million, versus $5.2 million a year earlier.
  • Cash, cash equivalents and restricted cash totaled approximately $11.2 million as of June 30, 2026.
  • Scienture reported expanded ARBLI payer coverage of approximately 12.5 million covered lives and REZENOPY formulary coverage with a large national health plan.
EARLY ACCESS
Receive SCNX Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$SCNX Hedge Fund Activity

We have seen 8 institutional investors add shares of $SCNX stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles